ORF Genetics Ltd.

Based in Iceland, ORF Genetics develops plant-based recombinant growth factors and cytokines, utilizing innovative molecular farming techniques to meet the demands of biotechnology and sustainable protein production. ORF Genetics, founded in 2001 in Kopavogur, Iceland, specializes in producing plant-derived recombinant proteins. The company has engaged in one significant deal, raising EUR 5 million on September 10, 2025, aimed at expanding its production capabilities for cultivated meat. The firm does not have any known subsidiaries or parent companies.

The founder's background details are unavailable. ORF Genetics specializes in the production of plant-based recombinant growth factors and cytokines, leveraging a proprietary expression system that utilizes barley grain as a production vehicle. The company's core product lines include ISOkine, which focuses on human growth factors; MESOkine, tailored for animal growth factors; and DERMOkine, which offers growth factors for both human and mouse applications. These products serve various industries, including stem cell research, skincare, biopharmaceuticals, and the cultivated meat sector, primarily serving clients in Europe, Asia, and North America.

The revenue structure of ORF Genetics is based on B2B transactions, focusing on partnerships with companies in the biopharmaceutical and cultivated meat industries. The company engages in direct sales of its growth factors, with clients purchasing products either through established contracts or one-time orders. Transactions are structured around volume and species specificity, allowing clients to benefit from tiered pricing based on order size. Flagship products like the ISOkine and MESOkine series are integral to revenue generation, targeting a niche market prioritizing animal-free and high-purity recombinant proteins, enhanced further by collaborations with partners like Vow and SeaWith.

In September 2025, ORF Genetics Ltd. raised EUR 5 million in venture funding to increase production of its barley-based growth factors for cultivated meat, addressing the rising demand in that market. The funding will support the development of new product lines and facilitate entry into additional markets, particularly focusing on expanding its presence in North America and Asia by 2026.